22nd September 2020 Product update: rapidmicrobiology staff writer
New Rapid Winter Flu, COVID-19 and Other Respiratory Viruses Test Is CE-Marked
GenMark Diagnostics has achieved CE Marking for its ePlex® Respiratory Pathogen Panel 2 (RP2).
The molecular test provides results in less than two hours for more than 20 viruses and bacteria that cause common and often serious respiratory infections, including COVID-19, influenza A and B, respiratory syncytial virus (RSV) and rhinovirus.
This panel was previously made commercially available in the U.S. and is awaiting Emergency Use Authorization by the FDA.
A syndromic diagnostic test, RP2 provides rapid results for infections with similar symptoms such as fever, cough and body aches, which will be critical in preparing for fall and winter as the flu season coincides with the ongoing risk of COVID-19.
After the 2016-2017 winter flu and virus season, York Teaching Hospitals in the United Kingdom (including a 700-bed hospital in York and a 300-bed hospital in Scarborough) switched to in-hospital multiplex testing with GenMark’s ePlex system. Offsite syndromic testing during the flu season resulted in slow turnaround time and negatively affected bed management, so the benefits of the GenMark RP panel were huge, leading to 9,111 bed days saved the first year (2017-2018) and 13,971 bed days the second year (2018-2019) compared to 2016-2017.1
RP2 includes a new, simplified workflow making it even easier for labs to run the test. Incorporating COVID-19 into the existing ePlex Respiratory Pathogen (RP) Panel streamlines the diagnostic process for hospitals by allowing them to check for multiple pathogens with a single test, saving time and resources and improving bed management.
A study at two acute large tertiary care hospitals demonstrated that using the ePlex RP panel in the Emergency Department led to earlier patient results, which resulted in an 8.4% reduction in hospital admissions.2
The ePlex RP2 Panel is designed for use with the company’s ePlex system, along with the ePlex RP Panel and Blood Culture Identification (BCID) Panels (Gram-positive, Gram-negative and Fungal pathogens), all of which have achieved CE Mark.
The ePlex RP2 Panel has been funded in part with federal funds from the United States Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00022.
Click here to learn more about the ePlex RP2 Panel.
1. Neish, B, et al. The Clinical Impact of Rapid Winter Respiratory Virus (WRV) Testing in the U.K., The Institute of Biomedical Science Congress 2019.
Date Published: 22nd September 2020
Source article link: View
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.
Pipette Tips Demonstrate High Bacterial
Latest Updates on COVID-19 Testing